CTKB
Cytek Biosciences, Inc.
CTKB lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
CTKB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
CTKB's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
CTKB PE Valuation
CTKB has no meaningful PE right now: it lost money over the past year.
CTKB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CTKB's losses to shrink, with revenue growing.
CTKB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | -$0.54 |
| Q2 2026 | -$0.63 | -$0.58 |
| Q1 2026 | -$0.58 | -$0.49 |
| Q4 2025 | -$0.52 | -$0.47 |
| Q3 2025 | -$0.10 | -$0.02 |
| Q2 2025 | -$0.05 | +$0.09 |
| Q1 2025 | -$0.09 | $0.00 |
| Q4 2024 | -$0.05 | +$0.04 |
CTKB lost $0.64 per share over the past year, and its loss has widened in each of the last five quarters.
CTKB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $53.2M | +1.8% |
| Q2 2026 | $48.1M | +5.6% |
| Q1 2026 | $44.1M | +6.5% |
| Q4 2025 | $62.1M | +8.1% |
| Q3 2025 | $52.3M | +1.5% |
| Q2 2025 | $45.6M | -2.2% |
| Q1 2025 | $41.5M | -7.6% |
| Q4 2024 | $57.5M | -1.3% |
CTKB's revenue has grown year over year for five quarters in a row: $53M last quarter, up 1.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -16% | +1.8 points |
| Q2 2026 | -24% | -0.4 points |
| Q1 2026 | -42% | -5.7 points |
| Q4 2025 | -9% | -14 points |
| Q3 2025 | -18% | -9.3 points |
| Q2 2025 | -23% | -5 points |
| Q1 2025 | -36% | -12 points |
| Q4 2024 | 5.2% | +5.4 points |
CTKB's operating margin was −16% last quarter, up 1.8 points from the same quarter a year ago.
CTKB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6M | -$1.4M |
| Q2 2026 | -$849K | +$620K |
| Q1 2026 | -$4.9M | -$3.9M |
| Q4 2025 | -$1.8M | -261% |
| Q3 2025 | -$4.6M | -137% |
| Q2 2025 | -$1.5M | -129% |
| Q1 2025 | -$974K | -129% |
| Q4 2024 | $1.1M | -86% |
CTKB has burned cash in seven of the last eight quarters: −$13M over the past year, against −$6M the year before.
CTKB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -431.1x | Net Cash |
| Q3 2022 | -185.1x | Net Cash |
| Q2 2022 | -100.0x | Net Cash |
| Q1 2022 | -48.1x | Net Cash |
| Q4 2021 | -37.2x | Net Cash |
| Q3 2021 | -23.1x | Net Cash |
| Q2 2021 | -7.9x | Net Cash |
| Q1 2021 | -10.0x | Net Cash |
CTKB has more cash than debt.
CTKB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.6 | Neutral |
| Stochastic | 77.2 | Neutral |
CTKB's weekly RSI is 57 (neutral) and its Stochastic is 77 (neutral).
CTKB PE vs Healthcare Sector
| Metric | CTKB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTKB has no meaningful PE right now: it lost money over the past year.
CTKB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.66 | 2.5% below |
| 20 week MA | $5.04 | 9.5% above |
| 50 week MA | $4.73 | 17% above |
| 100 week MA | $4.50 | 23% above |
| 200 week MA | $5.95 | 7.2% below |
CTKB's trend is mixed: it's above three of its five weekly moving averages, and 7.2% below its 200-week average.
CTKB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.8 | $17.3 | -8% |
| 2022 | $17.3 | $10.1 | -41% |
| 2023 | $10.1 | $9.12 | -9.9% |
| 2024 | $9.12 | $6.39 | -30% |
| 2025 | $6.39 | $5.10 | -20% |
| 2026 YTD | $5.10 | $5.52 | +8.2% |
CTKB has finished every year since 2021 lower, and it's up 8.2% so far in 2026.